AR and prostate carcinoma: There are several promising agents directly or indirectly targeting AR-Vs, but we need to keep in mind that AR signaling may not be required in later stages of prostate cancer progression when lineage plasticity emerges following AR-targeting therapies, and AR targeting approaches are generally not considered to be effective in the treatment of neuroendocrine/small cell prostate cancers [97].